Abstract 622P
Background
The modified mCCS intends to predict overall survival (OS) of mCRC patients (pts) at start of 1L therapy. Five clinical routine parameters assign pts into three prognostic risk groups from low to intermediate and high risk: tumor stage, tumor grading, lymph node ratio, primary tumor resection status and number of metastatic sites at start of 1L treatment (Marschner N, et al. Colorectal Dis. 2019). VALIDATE (NCT03043950) prospectively validates the mCCS in a large patient cohort with RAS WT mCRC.
Methods
VALIDATE is a multicenter, non-interventional study evaluating real-world effectiveness, safety and quality of life in pts with RAS WT mCRC receiving 1L PAN plus FOLFIRI/FOLFOX. Pts were allocated to three mCCS risk groups. This second interim analysis (IA2) was performed 24 months after last patient in. Data were analyzed descriptively for effectiveness, response rates and secondary resection rates.
Results
At data-base cut (Nov 17, 2022), 611 pts from 108 German and 5 Austrian sites were evaluable. Median age was 66.1 years, 68.9% of pts were male and 83.3% had an ECOG performance status 0/1. 59.4% of pts were diagnosed with a colon tumor. 84.3% of these pts had a left-sided tumor.
Table: 622P
Total N=611 | mCCS | |||
Low risk N=202 | Intermediate risk N=198 | High risk N=211 | ||
Overall response rate n (%) | 381 (62.4%) | 121 (59.9%) | 128 (64.6%) | 132 (62.6%) |
Secondary resections n (%) | 115 (18.8%) | 43 (21.3%) | 47 (23.7%) | 25 (11.8%) |
24-month OS rate [95%-CI] | 54.2% [50.0, 58.3] | 60.0% [52.4, 66.8] | 61.3% [53.8, 67.9] | 42.3% [35.3, 49.0] |
Most common grade 3/4 (MedDRA v20.0) treatment-emergent adverse drug reactions (TEADR) were dermatitis acneiform (5.8%), rash (2.9%) and diarrhea (3.2%). One investigator assessed fatal TEADR (arterial embolism) occurred.
Conclusions
The IA2 showed favorable effectiveness for PAN plus FOLFIRI/FOLFOX in the total population and in all mCCS risk groups in clinical routine in Germany and Austria. Interestingly, rates of secondary resections were >20% for low and intermediate risk pts. mCCS predicting OS will be validated in the final analysis. No new safety signals emerged.
Clinical trial identification
NCT03043950.
Editorial acknowledgement
Legal entity responsible for the study
iOMEDICO AG.
Funding
Amgen.
Disclosure
M. Reiser: Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. J. Uhlig: Financial Interests, Personal and Institutional, Advisory Board: Roche, Amgen, Servier, MSD, Bristol Myers Squibb, Sanofi, Merck, Celgene, Novartis, Janssen-Cilag, Boehringer Ingelheim, Bayer, BeiGene; Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. L. Jacobasch, L. Mueller: Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. A. Schuch, L. Serrer, R. de Buhr: Financial Interests, Personal, Full or part-time Employment: iOMEDICO. H.U. Siebenbach: Financial Interests, Personal, Full or part-time Employment: iOMEDICO. T. Göhler: Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. J.K. Schröder: Financial Interests, Personal and Institutional, Advisory Board: Celgene, Roche, Bristol Myers Squibb, Clovis Oncology, GSK, Boehringer Ingelheim, Amgen, Novartis, MSD, AOP, Searchlight, Pharma Partner, Medicline, Eisai, HE Research, Octapharma, AbbVie, NIO, I+E Pharma, ISPEN, BeiGene, Milteny; Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. D. Semsek: Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. A. Koehler: Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE; Financial Interests, Personal, Advisory Board: Roche, Novartis, Pfizer, Amge, Daiichi Sankyo MSD. P. Stübs: Non-Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. K.M. Potthoff: Financial Interests, Personal, Full or part-time Employment: iOMEDICO. N.W. Marschner: Non-Financial Interests, Personal and Institutional, Invited Speaker: Amgen, BeiGene, Roche, GSK, Euspharm, stemline, Seagen, Servier; Non-Financial Interests, Personal and Institutional, Advisory Board: Amgen, AstraZeneca, BeiGene, , Bristol Myers Squibb, Celgene, Daiichi Sankyo, Deciphera, Eisai, Eusapharm, Gilead, GSK, Janssen, Lilly, Mundipharma, Merck, Mylan, MSD, Novartis, Oncopeptides, Oncovis, Pfizer, Pierre Fabre, Roche, Seagen, Servier Stemline; Financial Interests, Personal and Institutional, Member of Board of Directors: iOMEDICO; Financial Interests, Personal and Institutional, Full or part-time Employment: iOMEDICO; Financial Interests, Institutional, Ownership Interest: iOMEDICO; Non-Financial Interests, Institutional, Research Grant: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Deciphera, Eisai, Eusapharm, Gilead, GSK, Janssen, Lilly, Mundipharma, Merck, Mylan, MSD, Novartis, Oncopeptides, Oncovis, Pfizer, Pierre Fabre, Roche, Seagen, Servier, Stemline; Non-Financial Interests, Institutional, Funding: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Deciphera, Eisai, Eusapharm, Gilead, GSK, Janssen, Lilly, Mundipharma, Merck, Mylan, MSD, Novartis, Oncopeptides, Oncovis, Pfizer, Pierre Fabre, Roche, Seagen, Servier, Stemline; Financial Interests, Personal, Project Lead: iOMEDICO/VALIDATE.
Resources from the same session
548P - Diffuse midline gliomas H3K27-altered in adults, the experience of an oncology center
Presenter: Carolina Trabulo
Session: Poster session 10
561P - Risk of colorectal cancer and premalignant lesions after kidney transplantation
Presenter: Koen Zwart
Session: Poster session 10
562P - Quantifying the effect of colonoscopy and polypectomy rates in stage shift of colorectal cancer and reduced need for adjuvant chemotherapy
Presenter: Mina Sarofim
Session: Poster session 10
563P - The impact of participation in colorectal cancer screening: A population-based results from Lithuania
Presenter: Tomas Poskus
Session: Poster session 10
564P - A large-scale real-world study for colorectal cancer screening
Presenter: Song LIU
Session: Poster session 10
565P - Real-world data of early-onset colon cancer (early-onset CC) from the AIO colopredict plus (CPP) registry: Clinical and molecular characteristics, treatment and outcome
Presenter: Doreen Gisder
Session: Poster session 10
566P - Long-term survivorship outcomes of adolescents and young adults (AYA) with cancer of the lower gastrointestinal tract
Presenter: Winette Van Der Graaf
Session: Poster session 10
567P - Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients: Results from the PETACC 8 study
Presenter: Elisabeth Bergen
Session: Poster session 10
568P - Single cell AI-based detection of DNA mismatch repair deficiency in 1,988 colorectal cancers reveals prognostic and predictive value in the SCOT trial
Presenter: Faiz Jabbar
Session: Poster session 10
569P - Artificial intelligence for detection of mismatch repair deficiency in colon carcinomas (alliance)
Presenter: Frank Sinicrope
Session: Poster session 10